Contact:

David K. Waldman/John W. Heilshorn	The Quigley Corporation
Lippert Heilshorn & Associates	Carl Fonash
(212) 838-3777	Shareholder Relations
dwaldman@lhai.com	(267) 880-1111

The Quigley Corporation Provides an Update of its Proposed Stock Dividend of Shares of Common Stock of Suncoast Naturals, Inc.

DOYLESTOWN, PA. - June 3, 2004 - The Quigley Corporation (Nasdaq: QGLY) release dated February 19, 2003, announced a distribution of 500,000 shares of common stock of Suncoast Naturals Inc., held in The Quigley Corporation's name, to stockholders of record on March 6, 2003. The distribution was made contingent upon the filing of a registration statement covering these shares by Suncoast Naturals, Inc. and it being declared effective. The registration statement is not yet effective, and thus, The Quigley Corporation will be required to set a new record date and notify its stockholders once the Securities and Exchange Commission declares the registration statement effective.

About The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading developer and marketer of diversified health products including the COLD-EEZE® family of patented zinc gluconate glycine (ZIGG™) lozenges and sugar free tablets. COLD-EEZE is the only (ZIGG) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc., (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally-derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND or take any other action to allow the aforementioned products to be studied or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.